A 48-Week, Randomised, Study to Describe the Pharmacokinetic Profile and Durability of Atazanavir-Saquinavir-Ritonavir Once Daily and Describe the Pharmacokinetic Profile of Saquinavir-Ritonavir Using Saquinavir 500mg Formulation: the ASK-500 Study

This study has been completed.
Sponsor:
Collaborator:
Hoffmann-La Roche
Information provided by:
Kirby Institute
ClinicalTrials.gov Identifier:
NCT00192608
First received: September 13, 2005
Last updated: June 25, 2009
Last verified: June 2009